3-Year Outcomes for Dolutegravir (DTG) + Lamivudine (3TC) in ART-Naive and Pre-treated People Living With HIV-1 (PLHIV) in Germany: Real-world Data From the German URBAN Cohort

<u>Sebastian Noe</u>,¹ Stefan Scholten,² Christoph Wyen,³ Michael Sabranski,⁴ Nils Postel,⁵ Olaf Degen,⁶ Daniel Beer,⁷ Kevin Ummard-Berger,⁸ Bernd Westermayer,⁹ Kathrin M. Dymek,¹⁰ Jenny Scherzer¹⁰

¹MVZ München am Goetheplatz, Munich, Germany; ²Praxis Hohenstaufenring, Cologne, Germany; ³Praxis Ebertplatz, Cologne, Germany; ⁴ICH Study Center, Hamburg, Germany; ³Praxis Ebertplatz, Cologne, Germany; ⁴ICH Study Center, Hamburg, Hamburg, ⁷Praxis Dr. H. Knechten, Aachen, Germany; ⁸UBN/Praxis, Berlin, Germany; ⁹GSK, Munich, Germany; ¹⁰ViiV Healthcare, Munich, Germany

Key Takeaways

- **URBAN** is a prospective, non-interventional, 3-year cohort study in antiretroviral therapy (ART)-naive and pre-treated people living with HIV-1 (PLHIV) receiving dolutegravir and lamivudine (DTG + 3TC) in Germany
- **DTG + 3TC maintained high rates of virologic** suppression after 3 years in both pre-treated and ART-naive PLHIV in a real-world setting
- Through 3 years of DTG + 3TC treatment, changes in lipid and liver parameters from baseline were minimal
 - Significant improvements in treatment satisfaction were observed in pre-treated individuals through 3 years

Introduction

- Although clinical trials have assessed DTG + 3TC for first-line therapy and maintenance of virologic suppression,¹⁻³ clinical practice observations can complement these data in more diverse populations
- The URBAN study provides real-world data on effectiveness, tolerability, metabolic parameters, and patient-reported outcomes (PROs) in PLHIV using DTG + 3TC
- Here we present Year 3 results

Methods

- URBAN is a prospective, non-interventional, multi-center, 3-year German cohort study (initiated 11/2018) in ART-naive and pre-treated PLHIV receiving DTG + 3TC in accordance with the label
- DTG + 3TC was used as a 2-pill regimen and/or a 1-pill regimen (after availability in 7/2019)
- Inclusion criteria for the Year 3 full analysis set were a documented Year 3 follow-up or treatment discontinuation

Outcomes

- The primary endpoint was proportion of individuals with virologic suppression (HIV-1 RNA <50 or 50-200 c/mL with subsequent HIV-1 RNA <50 c/mL within 120 days; discontinuation = failure) at 3-year follow-up
- A key exploratory endpoint was proportion of individuals with virologic suppression (HIV-1 RNA <50 c/mL) through 3 years based on missing = excluded (M = E) and discontinuation = failure (D = F; individuals discontinuing DTG + 3TC before the visit window had viral load imputed as ≥50 c/mL) analyses
- Virologic failure was not protocol-defined in this real-world study; however, investigators could discontinue a person at any time for "virologic reasons" at their discretion
- Tolerability, lipids, and liver parameter changes were evaluated at 3-year follow-up
- PROs were assessed via the HIV Treatment Satisfaction Questionnaire, status version (HIV-TSQs)⁴ and the HIV Symptom Distress Module (HIV-SDM)⁵

Results

Study Population

Table 1. Demographics and Baseline Characteristics

Parameter

Age, median (range), y <50 y, n (%)

50-65 y, n (%)

>65 y, n (%) Sex, male, n (%)

BMI, median (IQR), kg/m

HIV-1 RNA, median (IQR) <50 c/mL, n (%) 50 to <200 c/mL, n (%)

200 to 100,000 c/mL, r >100,000 c/mL, n (%)

CD4+ cell count, median <200 cells/mm³, n (%)

Time on ART, median (IC

No. of treatment switche Still on first-line ART

Unknown Most common (≥5%) pr

DTG/ABC/3TC DTG + FTC/TAF **BIC/FTC/TAF**

DTG + FTC/TDF

EVG/COBI/FTC/TAF

Most common comorbid

Depression (acute or s Hypertension Lipidemia disorder Chronic kidney insuffici Insomnia

Virologic Suppression

- Rates of virologic suppression through 3 years were high in both M = E and D = F analyses in pre-treated and ART-naive individuals (Figure 1B-C)
- Overall, 1.8% (6/332) of individuals discontinued DTG + 3TC for virologic reasons at investigator's discretion with HIV-1 RNA \geq 50 c/mL (n=5 pre-treated, n=1 ART-naive) • HIV-1 RNA at discontinuation was 138, 89, 540, 83, and 128 c/mL (pre-treated) and 95 c/mL (ART-naive)
- In 1 pre-treated individual without a historical resistance test, integrase mutations T97A, E138K, and N155H were detected at Month 24 (HIV-1 RNA 540 c/mL), which in combination confer low-level resistance to DTG.⁶ Viral load was re-suppressed (<40 c/mL) at treatment discontinuation at Month 25. HIV history other than immediate prior ART (DTG + TAF/FTC) is unknown. Participant switched to DRV/c/FTC/TAF + DTG


• Among 366 individuals, median baseline age was 47 years; 93.2% were male (Table 1) • Overall, 332/366 (90.7%) individuals were eligible for the primary analysis; those with missing data (n=8) or lost to follow-up (n=26) were excluded • In pre-treated individuals, median time on ART before switch to DTG + 3TC was


7 years (IQR, 4-13; n=303), and 32.8% had a history of \geq 3 ART switches

	ART-naive	Pre-treated	
	(N=31)	(N=335)	
	35 (21-55)	49 (22-82)	
	26 (83.9)	180 (53.7)	
	5 (16.1)	135 (40.3)	
	0	20 (6.0)	
	30 (96.8)	311 (92.8)	
1 ²	23 (21-25)	25 (23-28)	
2), c/mL	37,200 (5100-70,700)	19 (0-39)	
	0	324 (96.7)	
)	2 (6.5)	7 (2.1)	
n (%)	26 (83.9)	3 (0.9)	
	3 (9.7)	1 (0.3)	
n (IQR), cells/mm³	456 (328-664)	748 (549-940)	
	4 (12.9)	2 (0.6)	
QR), y	NA	7 (4-13)	
es, n (%)			
	NA	56 (16.7)	
		143 (42.7)	
		110 (32.8)	
		26 (7.8)	
or ART regimens, n (%)			
	NA	148 (44.2)	
		42 (12.5)	
		25 (7.5)	
		20 (6.0)	
		17 (5.1)	
dities (>10%), n (%) ^a			
status post)	3 (9.7)	114 (34.0)	
	1 (3.2)	85 (25.4)	
	1 (3.2)	45 (13.4)	
ciency	0	40 (11.9)	
	2 (6.5)	35 (10.4)	

ABC, abacavir; BIC, bictegravir; COBI, cobicistat; DTG, dolutegravir; EVG, elvitegravir; FTC, emtricitabine; NA, not applicable; TAF, tenofovir alafenamide; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate. aRelevant concomitant diseases according to ICD-10 chapter (per participant total, multiple answers possible

• Year 3 virologic suppression rates were 83.0% (253/305) for pre-treated and 77.8% (21/27) for ART-naive individuals (Figure 1A)





Tolerability

- The most common ADRs (Medical Dictionary for Regulatory Activities [MedDRA] preferred term; n >1) were depression (n=5), sleep disorder (n=2), and headache (n=2)
- 2 serious ADRs were reported in 2 individuals (MedDRA preferred term: anemia, fall, brachial plexus injury, concussion, and hyponatremia)
- 59 non-treatment-related serious adverse events were documented in 39 individuals (10.7%)
- 15 individuals discontinued due to intolerability (4.1%; n=12 pre-treated, n=3 ART-naive)
- The most common ADRs (MedDRA system organ class) leading to discontinuation were psychiatric disorders (n=10), skin and subcutaneous tissue disorders (n=3), and nervous system disorders (n=2)

Metabolic Parameters

- decision, 3 patient wish)

Patient-Reported Outcomes

- observed at Years 1 and 2^{7,8}
- HIV-SDM scores remained stable (Table 2)

Acknowledgments: This study was funded by ViiV Healthcare. Data analysis was performed by MUC Research. Editorial assistance and graphic design support for this poster were provided under the direction of the authors by MedThink SciCom and funded by ViiV Healthcare. Special thanks to the participants and investigators for the URBAN study centers: GP Isarpraxis/Munich; ICH/Hamburg; IZ Steglitz/Berlin; Klinikum Osnabrueck/Osnabrueck; MEDCENTER/Weimar; MVZ München am Goetheplatz/Munich; Onkologie Mannheim/Mannheim; Praxis City Ost/Berlin; Praxis Cordes/Berlin; Praxis Ebertplatz/Cologne; Praxis Hohenstaufenring/Cologne; Praxis Jessen/Berlin; Praxis Kaiserdamm/Berlin; Praxis Knechten/Aachen; Praxis UBN/Berlin; Praxis Wuensche/Berlin; PRINZMED/Munich; Universitätsklinikum Hamburg/Hamburg; WIR/Bochum.

References: 1. Cahn et al. AIDS. 2022;36:39-48. 2. Osiyemi et al. Clin Infect Dis. 2022;75:975-986. 3. Llibre et al. Clin Infect Dis. 2023;76:720-729. 4. Woodcock and Bradley. Qual Life Res. 2001;10:517-531. 5. Justice et al. J Clin Epidemiol. 2001;54(suppl 1):S77-S90. 6. Stanford University HIV Drug Resistance Database. https://hivdb.stanford.edu/. Accessed September 25, 2023. 7. Scholten et al. EACS 2021; London, UK. Poster PE2/52. 8. Beer et al. HIV Drug Therapy Glasgow 2022; Glasgow, Scotland. Poster P117.

• Overall, 4 treatment discontinuations due to weight gain were reported (pre-treated; 1 investigator)

 Among individuals with weight data at both time points, median (IQR) weight change from baseline at Year 3 was 2.0 kg (-1.0, 6.0; n=131) in pre-treated and 5.0 kg (1.0-10.0; n=13) in ART-naive individuals • Lipid and liver parameter changes from baseline were minimal (Figure 2)

 Pre-treated individuals who completed baseline and Year 3 questionnaires had statistically significantly increased HIV-TSQs scores at Year 3 (Figure 3), consistent with the significant improvements

HIV-SDN

Pre-treated ART-naive HIV-SDM, HIV Sympto

Limitations

eP.A.072



Year 3

Mean (SD) change from baseline in HIV-TSQs total score

HV-TSQs: 10-item version. Range per item is 0-6: 0 = "very dissatisfied" and 6 = "very satisfied." Total score = sum of items 1-10; range for total score is 0-60; positive changes indicate improvement.⁴ HIV-TSQs scores were not assessed at baseline in ART-naive individuals; mean (SD) HIV-TSQs score at Year 3 was 58.9 (2.0; n=12). aWilcoxon signed rank test.

Table 2. HIV-SDM Scores for Individuals Completing Both Baseline and **Year 3 Questionnaires**

				Change from baseline	
total score ^a	n	Baseline	Year 3	at Year 3	P value
ed, mean (SD)	165	14.2 (12.2)	14.3 (12.4)	0.1 (9.6)	0.7607 ^b
e, mean (SD)	10	10.8 (10.1)	7.6 (8.7)	-3.2 (8.0)	c
notom Distress Module a20-item	questionnaire	with total score ranging from	0-80: decreases indicate im	provement ⁵ bWilcoxon signed rank test ©Due to sma	all sample size

istress Module. a20-item questionnaire with total score ranging from 0-80; decreases indicate improvement. HIV-SDM scores in ART-naive individuals were not analyzed for statistically significant differences from baseline

 Fewer than half of the total population had available data at baseline and Year 3 for the weight and PRO analyses

Conclusions

• Over 3 years, high virologic suppression rates with DTG + 3TC were observed Few discontinuations for virologic reasons were reported; integrase resistanceassociated mutations conferring low-level resistance to DTG were detected in 1 participant at Month 24

 Treatment was well tolerated, with minimal changes in lipid and liver parameters Pre-treated individuals maintained statistically significant improvements in treatment satisfaction at Year 3, consistent with findings from Years 1 and 2 and supporting stable improvements in treatment satisfaction^{7,8}



This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their licence. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.

19th European AIDS Conference; October 18-21, 2023; Warsaw, Poland